Anticlotting drugs and regional anaesthetic and analgesic techniques: Comparative update of the safety recommendations

European Journal of Anaesthesiology

Volumn 24, Issue 5, 2007, Pages 387-398

  Llau, J V ^a   Andrés, J De ^b   Gomar, C ^c   Gomez Luque A ^d   Hidalgo, F ^e   Torres, L M ^f  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

Author keywords

Blood coagulation; Conduction anaesthesia; Drug interactions; Guidelines; Heparin; Platelet aggregation inhibitors; Venous thrombosis, prophylaxis

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BEMIPARIN; CLOPIDOGREL; DALTEPARIN; DANAPAROID; DESULFATOHIRUDIN; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HIRUDIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; THIENO[2,3 B]PYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN; TRIFLUSAL; WARFARIN;

ANALGESIA; ANESTHESIOLOGY; COMPARATIVE STUDY; CONSENSUS; DEEP VEIN THROMBOSIS; DRUG POTENTIATION; DRUG SAFETY; HEMOSTASIS; HOSPITAL DEPARTMENT; HUMAN; MEDICAL PRACTICE; PRACTICE GUIDELINE; REGIONAL ANESTHESIA; REVIEW; SAFETY;

ANALGESIA; ANESTHESIA, CONDUCTION; ANTICOAGULANTS; DRUG INTERACTIONS; HUMANS; PRACTICE GUIDELINES; SOCIETIES, MEDICAL; SPAIN;

EID: 34247620311     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021506001918     Document Type: Review

References (47)

1. Horlocker TT, Wedel DJ, Schoroder SH, Elliot BA, McGregor DG, Wong GY. Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia. Anest Analg 1995; 80: 303-309.
2. Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient: Defining the risks. Reg Anesth Pain Med 2004; 29(Suppl 1): 1-11.
3. Llau JV, De Andrés J, Gomar C et al. Drugs that alter hemostasis and regional anesthetic techniques: safety guidelines. Consensus conference (Spanish). Rev Esp Anestesiol Reanim 2001; 48: 270-278.
4. Gogarten W, Van Aken H, Büttner J, Riess H, Wulf H, Buerkle H. Rückenmarksnahe Regionalanästhesien und Thromboembolieprophylaxe / antithrombotische Medikation. Überarbeitete Leitlinien der Deustchen Gesellschaft für Anästhesiologie und Intensivmedizin. Anästh Intensivmed 2003; 44: 218-230.
5. Horlocker TT, Wedel DJ, Benzon H et al. Regional anesthesia in the anticoagulated patient: Defining the risks (The Second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28: 172-197.
6. Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, Gómez Luque A, Hidalgo Martínez F, Torres Morera LM. Guidelines of hemostasis inhibiting drugs and neuraxial anaesthesia (Spanish). Rev Esp Anestesiol Reanim 2005; 52: 413-420.
7. Kozek-Langenecker SA, Fries D, Gütl M et al. Lokoregionalanästhesien unter gerinnungshemmender Medikation. Anaesthesist 2005; 54: 476-484.
8. Vandermeulen E, Singelyn F, Vercauteren M, Brichant JF, Ickx BE, Gautier P. Belgian guidelines concerning central neural blockade in patients with drug induced alteration of coagulation: an update. Acta Anaesthesiol Belg 2005; 56: 139-146.
9. Samama CM, Bastien O, Forestier F et al, and the expert group. Antiplatelet agents in the perioperative period: expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001 - Summary statement. Can J Anesth 2002; 49: S26-S35.
10. Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, Gómez Luque A, Hidalgo Martínez F, Torres Morera LM. Hemostasis-altering drugs and techniques for regional anaesthesia and analgesia: safety recommendations (Spanish). Rev Esp Anestesiol Reanim 2005; 52: 248-250.
11. Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, Gómez Luque A, Hidalgo Martínez F, Torres Morera LM. Hemostasis-altering drugs and regional anaesthetic techniques: safety guidelines (Spanish). Rev Esp Anaestesiol Reanim 2004; 51: 137-142.
12. Llau Pitarch JV, De Andrés Ibáñez J, Gomar Sancho C, Gómez Luque A, Hidalgo Martínez F, Torres Morera LM. European Society for Regional Anaesthesia: Locoregional anaesthesia and drugs that affect hemostasis. Suggestions of the expert meeting in the ESRA Congress in Barcelona. Rev Esp Anestesiol Reanim 2002; 49: 468-473.
13. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest 2001; 119 (Suppl): 132S-175S.
14. Turpie AG. State of the art - a journey through the world of antithrombotic therapy. Semin Thromb Hemost 2002; 28(Suppl 3): 3-11.
15. Horlocker TT, Wedel DJ. Neuraxial block and low-moleular-weight heparin: balancing perioperative analgesia and thromboprophylaxis. Reg Anesth Pain Med 1998; 23(Suppl 2): 164-177.
16. Tryba M. European practice guidelines: thromboembolism prophylaxis and regional anesthesia. Reg Anesth Pain Med 1998; 23(Suppl 2): 178-182.
17. Lee BB. Neuraxial complications after epidural and spinal anaesthesia. Acta Anaesthesiol Scand 2003; 47: 371-373.
18. Tyagi A, Bhattacharya A. Central neuraxial blocks and anticoagulation: a review of current trends. Eur J Anaesthesiol 2002; 19(5): 317-329.
19. Franchini M. The platelet function analyzer (PFA-100): an update on its clinical use. Clin Lab 2005; 51: 367-372.
20. Mandal NJ. PFA-100 and regional anesthesia. Br J Anaesth 2004; 93: 468.
21. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9: 407-415.
22. Tyagi A, Bhattacharya A. Central neuraxial blocks and anticoagulation: a review of current trends. Eur J Anaesthesiol 2002; 19: 317-329.
23. Mentegazzi F, Danelli G, Ghisi D, Tosi M, Gennari A, Fanelli G. Locoregional anesthesia and coagulation. Minerva Anestesiol 2005; 71: 497-499.
24. Geerts WH, Pineo GF, Heit JA et al. Prevention of venous thromboembolism. Chest 2004; 126: 338S-400S.
25. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
26. Hirsh J, Warkentin TE, Shaughenessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(Suppl): 64S-94S.
27. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematology 2003; 121: 12-20.
28. Strebel N, Prins N, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-1456.
29. Llau Pitarch JV, Ferrandis Comes R, García-Pérez ML. Regional anaesthesia, thromboprophylaxis and their relationship with the spinal hematoma: Spanish experience (Spanish). Med Clin (Barc) 2003; 121: 414-417.
30. Tufano A, Cerbone AM, Di Minno G. The use of antithrombotic drugs in older people. Minerva Med 2002; 93: 13-26.
31. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet active drugs: the relationships among dose, effectiveness, and side effects. Chest 2004; 126: 234S-264S.
32. CLASP (Collaborative Low-Dose Aspirin Study in Pregnancy): a randomized trial of low dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. Lancet 1994; 343: 619-629.
33. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group: prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: pulmonary embolism prevention (PEP). Lancet 2000; 355: 1295-1302.
34. Kövesi T, Royston D. Is there a bleeding problem with platelet-active drugs? (Editorial). BJA 2002; 88: 159-162.
35. Burger W, Chemnitus JM, Kneissl GD, Rücher G. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation- review. J Inter Med 2005; 257: 399-414.
36. Tam NL, Pac-Soo C, Pretorius PM. Epidural haematoma after a combined spinal-epidural anaesthetic in a patient treated with clopidogrel and dalteparin. Br J Anaesth 2006; 96: 262-265.
37. Litz RJ, Gottschlich B, Stehr SN. Spinal epidural hematoma after spinal anesthesia in a patient treated with clopidogrel and enoxaparin. Anesthesiology 2004; 101: 1467-1470.
38. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin k antagonists. Chest 2004; 126: 204S-233S.
39. Dunn A, Turpie AGG. Perioperative management of patients on oral anticoagulants: a systematic review. Arch Intern Med 2003; 163: 901-908.
40. Hirsh J, Raschke R. Heparin and low molecular-weight heparin. Chest 2004; 126: 188S-203S.
41. Cantó M. Regional anaesthesia in cardiac surgery. Future or reality? (Ed) (Spanish). Rev Esp Anestesiol Reanim 2003; 50: 319-325.
42. Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs. Chest 2004; 126: 265S-286S.
43. Donat F, Duret JP, Santoni A et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41(Suppl 2): 1-9.
44. Bauer KA, Hawkins DW, Peters PC et al. Fondaparinux, a syntetic pentasaccharide: the first of a new class of antithrombotic agents - the selective factor Xa inhibitors. Cardiovasc Drug Rev 2002; 20: 37-52.
45. Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62: 1673-1685.
46. Westphal M, Booke M. Zum neuartigen Antithrombotikum Fondaparinux. Anästh Intensivmed 2003; 44: 324-325.
47. Singelyn FJ, Felicissimo P, Piovella F et al. Extended thromboprophylaxis with fondaparinux (Arixtra) after major orthopedic lower limb surgery: the EXPERT study. Oral Presentation, Lisbon EFORT, 2005, June 4-7 2005.